Back to today’s briefing

Story perspectives

Recursion Pharmaceuticals Faces $171.9M Loss Amid Drug Trials

10/20/2025

27 6 Full Breakdown

Summary

Story summary

Recursion Pharmaceuticals, Inc. reports a net loss of $171.9 million on $58.49 million in revenue, while its stock fell 7.23%.
Analysts have lowered Q3 2025 earnings estimates to a loss of $0.31 per share.
Institutional investors hold 89.06% of the stock.
The company is advancing multiple drugs in clinical trials, including REC-994 for cerebral cavernous malformation.

History

Historical Context

The 2008 financial crisis severely impacted the pharmaceutical sector, causing a 30% decline in stock values. Recursion Pharmaceuticals, Inc. reported a net loss of $171.9 million, reflecting ongoing challenges in drug development. With institutional investors holding 89.06% of its stock, the situation highlights the volatility in the pharmaceutical industry and raises concerns about future funding and drug approval processes.

1 of 2

Story summary

Recursion Pharmaceuticals, Inc. reports a net loss of $171.9 million on $58.49 million in revenue, while its stock fell 7.23%.
Analysts have lowered Q3 2025 earnings estimates to a loss of $0.31 per share.
Institutional investors hold 89.06% of the stock.
The company is advancing multiple drugs in clinical trials, including REC-994 for cerebral cavernous malformation.

1 / 2